We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Onyx Pharmaceuticals, Inc. (MM) | NASDAQ:ONXX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 124.70 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
Amgen Inc.'s (AMGN) proposed $130-a-share, or $9.5 billion, takeover of Onyx Pharmaceuticals Inc. (ONXX) has stalled over access to drug trial data, although the offer price itself is not at issue, Bloomberg News reported Thursday on its website, citing three people familiar with the matter.
The deal is being slowed over whether Onyx will provide to Amgen data on a blood-cancer treatment which is in the midst of a trial. Because the trial is ongoing, Onyx doesn't have access to the data and obtaining the results prior to conclusion of the study could slow the drug's approval, one person told Bloomberg.
A spokeswoman for Onyx declined comment to Bloomberg and a spokeswoman for Amgen said the company doesn't comment on market rumors.
Full story at: www.bloomberg.com/news/2013-08-15/amgen-talks-to-buy-onyx-said-to-stall-on-drug-trial-data.html
Write to nymonitoring@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Onyx Pharmaceuticals, Inc. (MM) Chart |
1 Month Onyx Pharmaceuticals, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
